1. Scrip
  2. >>Scrip Asks

Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds

Tough Times Call For Resilience, Flexibility And Collaboration

 
• By Eleanor Malone

Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.

Scrip Asks Part 3
• Source: Shutterstock

For the third installment of our Scrip Asks…What Does 2023 Hold For Biopharma? series, we asked industry leaders and experts how the sector would be affected by the global headwinds of political instability, violent conflict, inflation and recession.

Most acknowledged that times are tough and that biopharma cannot remain untouched by the political and macroeconomic situation. In the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

More from Scrip

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By Mandy Jackson

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 
• By Jessica Merrill

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.